Jubilant Life Sciences today said it has received approval from the US health regulator to market generic Sporanox capsules, used to treat fungal infections, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for Itraconazole capsules, a generic version of Janssen Pharmaceuticals' Sporanox, Jubilant Life Sciences said in a regulatory filing.
As on December 31, 2016 Jubilant had a total of 73 abbreviated new drug applications (ANDAs) for oral solids filled in the US, of which 49 have been approved.
Shares of the company were trading 1.8 percent up at Rs 720.30 apiece on BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
